MICHELLE SIMMONS: Open Payments
NPI 1306215660 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$874 in 20 payments from 10 companies in 2025. Trend: 2023 $1,816 · 2024 $1,815 · 2025 $874
Food & beverage: $874
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 1 | $135 |
| GENZYME CORPORATION | 1 | $122 |
| Grifols USA, LLC | 1 | $116 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $115 |
| VERTEX PHARMACEUTICALS INCORPORATED | 5 | $113 |
| Averitas Pharma Inc. | 3 | $87 |
| ABBVIE INC. | 3 | $62 |
| SPR Therapeutics, Inc | 2 | $55 |
| Medtronic, Inc. | 2 | $41 |
| Boston Scientific Corporation | 1 | $29 |
Products named: AUSTEDO XR, FABRAZYME, Prolastin-C Liquid, JOURNAVX, QUTENZA, BOTOX, SPRINT PNS System, Intracept.
Industry payments across TX — which companies pay providers there.
